Physician profile
Stanley E Rowan
NPI 1447286166
$794.80
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $683 · 2020: $112.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $183.11 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $115.52 | 2019 | |
| Novo Nordisk INC | $106.50 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.24 | 2019 | |
| Pfizer INC. | $76.27 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $74.67 | 2019-2020 | |
| Glaxosmithkline, LLC. | $62.76 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $34.21 | 2019 | |
| Sanofi-Aventis U.S. LLC | $31.12 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.61 | 2019 | |
| Amgen INC. | $12.79 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Rowan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.